Odyral (Dorzolamide)

Dorzolamide blocks the activity of carbonic anhydrase II in the ciliary body, which reduces the production of aqueous humor. The resulting decrease in fluid volume lowers intra‑ocular pressure, thereby mitigating the risk of optic nerve damage associated with glaucoma.

The dosing schedule is determined by the prescribing ophthalmologist. Typically, one drop is instilled in each affected eye one to three times daily, but the exact frequency and duration are individualized based on the patient’s response and clinical judgment.

Dorzolamide is classified as pregnancy category C, meaning animal studies have shown risk and there are no adequate human studies. It should be used only if the potential benefit justifies the potential risk to the fetus. The drug can be excreted in breast milk, so nursing mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Odyral product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Odyral (dorzolamide) belongs to the carbonic anhydrase inhibitor class, offering a mechanism distinct from beta‑blockers (e.g., timolol) or prostaglandin analogues (e.g., latanoprost). Compared with brinzolamide, another CAI, dorzolamide has a similar efficacy profile but may differ in tolerability for some patients. Choice of therapy depends on individual response, side‑effect profile, and physician preference.

Odyral should be stored at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain sterility and potency.

Odyral is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill one drop into the conjunctival sac of each prescribed eye. Avoid touching the tip of the bottle to the eye or any surface to prevent contamination.

The most serious adverse events include severe allergic reactions such as angio‑edema or anaphylaxis, Stevens‑Johnson syndrome, corneal edema, and rare cases of systemic metabolic acidosis. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or eyes, skin blistering, or sudden vision changes.

Odyral is contraindicated in patients with a known hypersensitivity to dorzolamide, sulfonamides, or any component of the formulation. It should also be avoided in individuals with severe renal or hepatic impairment unless specifically advised by a physician, and in patients who wear contact lenses during treatment unless the lenses are removed before each dose.